A Study With SAGE-547 for Super-Refractory Status Epilepticus
Study sponsor: Supernus Pharmaceuticals, Inc. · SUPN
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2017-07-18Actual
Enrollment · participants132Actual
Source updated2025-10-14Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.